Additional candidates to conventional genes susceptible for lung cancer and changing trend in Japan

Oncology Reports

Volumn 23, Issue 6, 2010, Pages 1493-1500

  Okazaki, Isao ^a   Sugita, Minoru ^b   Matsuki, Hideaki ^c   Billah, Syed Muhammad Baqui ^c   Watanabe, Tetsu ^c  

^a INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gene polymorphism; Lung cancer; Meta analysis; Smoking; Susceptible genes

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 2A; CYTOCHROME P450 2B; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SULFOTRANSFERASE 1A1; TUMOR PROTEIN;

ADENOCARCINOMA; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; DNA POLYMORPHISM; ENVIRONMENTAL CHANGE; GENE EXPRESSION; GENE FREQUENCY; GENE INTERACTION; GENETIC ANALYSIS; GENETIC LINKAGE; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; JAPAN; LUNG CANCER; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEX RATIO; SMOKING; SYSTEMATIC REVIEW; ASIAN CONTINENTAL ANCESTRY GROUP; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; LUNG NEOPLASMS;

ASIAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS;

EID: 77951855781     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000788     Document Type: Review

References (76)

1. Boddy AB and Ratain MJ: Pharmacogenetics in cancer etiology and chemotherapy. Clin Cancer Res 3: 1025-1030, 1997.
2. Kiyohara C, Hirohata T and Inutsuka S: The relation between aryl hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res 87: 18-24, 1996.
3. Hecht SS: Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol 3: 461-469, 2002.
4. Brockmoeller J, Cascorbi I, Kerb R, Sachse C and Roots I: Polymorphisms in xenobiotic conjugation and disease predisposition. Toxicol Lett 102-3: 173-183, 1998.
5. Oyama T, Matsumoto A, Isse T, Kim YD, Ozaki S, Osaki T, Sugio K, Yasumoto K and Kawamoto T: Evidence-based prevention (EBP): approach to lung cancer prevention based on cytochrome 1A1 and cytochrome 2E1 polymorphism. Anticancer Res 23: 1731-1738, 2003.
6. 3801 C polymorphism and lung cancer: a pooled analysis of 2,451 cases and 3,358 controls. Int J Cancer 104: 650-657, 2003.
7. Vineis P, Anttila S, Benhamou S, et al: Evidence of gene-gene interactions in lung carcinogenesis in a large pooled analysis. Carcinogenesis 28: 1902-1905, 2007.
8. Houlston RS: CYP1A1 polymorphisms and lung cancer risk: a meta-analysis. Pharmacogenetics 10: 105-114, 2000.
9. Hivronen A, Husgafvel-Pursianin A, Karjalanen S, Anttila S and Vainio H: Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev 1: 485-1459, 1992.
10. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N and Watanabe J: Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. FEBS 263: 131-133, 1990.
11. Nakachi K, Imai K, Hayashi S, Watanabe J and Kawajiri K: Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 51: 5177-5180, 1991.
12. Hayashi S, Watanabe J and Kawajiri K: High susceptibility to lung cancer analyzed in terms of combined genotypes of P4501A1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res 83: 866-870, 1992.
13. Nakachi K, Imai K, Hayashi S and Kawajiri K: Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 53: 2994-2999, 1993.
14. Kihara M, Kihara M and Noda K: Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population. Carcinogenesis 16: 2331-2336, 1995.
15. Nakachi K, Hayashi S, Kawajiri K and Imai K: Association of cigarette smoking and CYP1A1 polymorphisms with adenocarcinoma of the lung by grades of differentiation. Carcinogenesis 16: 2209-2213, 1995.
16. Kiyohara C, Nakanishi Y, Inutsuka S, Takayama K, Hara N, Motohiro A, Tanaka K, Kono S and Hirohata T: The relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population. Pharmacogenetics 8: 315-323, 1998. (Pubitemid 28372325)
17. Alexandrie A-K, Nyberg F, Warholm M and Rannug A: Influence of CYP1A1, GSTM1, GSTT1, and NQO1 genotypes and cumulative smoking dose on lung cancer risk in a Swedish population. Cancer Epidemiol Biomarkers Prev 13: 908-914, 2004.
18. Le Marchand L, Guo C, Benhamou S, et al: Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer Causes Control 14: 339-346, 2003.
19. Hung RJ, Boffetta P, Brockmoller J, et al: CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. Carcinogenesis 24: 875-882, 2003.
20. Belogubova EV, Ulibina YM, Suvorova, et al: Combined CYP1A1/GSTM1 at-risk genotypes are overrepresented in squamous cell lung carcinoma patients but underrepresented in elderly tumor-free subjects. J Cancer Res Clin Oncol 132: 327-331, 2006.
21. Vineis P, Veglia F, Anttila S, et al: CYP1A1, GSTM1 and GSTT1 polymorphisms and lung cancer: a pooled analysis of gene-gene interactions. Biomarkers 9: 298-305, 2004.
22. Sunaga N, Kohno T, Yanagitani N, et al: Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility. Cancer Epidemiol Biomarker Prev 11: 730-738, 2002.
23. Osawa Y, Osawa K, Miyaishi A, et al: NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status. Asian Pac J Cancer Prev 8: 103-108, 2007.
24. Vineis P, Veglia F, Garte S, et al: Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in non-smokers. Ann Oncol 18: 1230-1242, 2007.
25. Chiou HL, Wu MF, Chien WP, Cheng YW, Wong RH, Chen CY, Lin TS and Lee H: NAT2 fast genotype is associated with an increased risk of lung cancer among never-smoking women in Taiwan. Cancer Lett 223: 93-101, 2005.
26. Wang Y, Spitz MR, Tsou AM, Zhang K, Makan N and Wu X: Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: a case-control analysis. Lung Cancer 35: 137-142, 2002.
27. Wiencke JK, Spitz MR, McMillan A and Kelsey KT: Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H:quinine oxidoreductase polymorphism. Cancer Epidemiol Biomark Prev 6: 87-92, 1997.
28. Chen H, Lum A, Seifried A, Wilkens LR and LeMarchand L: Association of the NAD(P)H:quinine oxidoreductase 609C->T polymorphism with a decreased lung cancer risk. Cancer Res 59: 3045-3048, 1999.
29. Lin P, Wang HJ, Lee H, Lee HS, Wang SL, Hsueh YM, Tsai KJ and Chen CY: NAD(P)H:quinine oxidoreductase polymorphism and lung cancer in Taiwan. J Toxicol Environ Health A 58: 187-197, 1999.
30. Kiyohara C, Yoshimasu K, Takayama K and Nakanishi Y: NQO1, MPO, and the risk of lung cancer: a HuGE review. Genet Med 7: 463-478, 2005.
31. Larsen JE, Colosimo ML, Yang IA, Bowman R, Zimmerman PV and Fong KM: CYP1A1 Ile462Val and MPO G-463A interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung. Carcinogenesis 27: 525-532, 2006.
32. Hung RJ, Hall J, Brennan P and Boffetta P: Genetic polymorphisms in the Base Excision repair pathway and cancer risk: a HuGE review. Am J Epidemiol 162: 925-942, 2005.
33. Hung RJ, Brennan P, Canzian F, et al: Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study. J Natl Cancer Inst 97: 567-576, 2005.
34. Hung RJ, McKay JD, Gaborieau V, et al: A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452: 633-637, 2008.
35. Thorgeirsson TE, Geller F, Sulem P, et al: A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452: 638-642, 2008.
36. Amos CI, Wu X, Broderick P, et al: Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nature Genet 40: 616-622, 2008.
37. Lin P, Wang SL, Wang HJ, Chen KW, Lee HS, Tsai KJ, Chen CY and Lee H: Association of CYP1A1 and microsomal epoxide hydrolase polymorphisms with lung squamous cell carcinoma. Brit J Cancer 82: 852-857, 2000.
38. Song N, Tan W, Xing D and Lin D: CYP1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis 22: 11-16, 2001.
39. Ng DPK, Tan K-W, Zhao B and Seow A: CYP1A1 polymorphisms and risk of lung cancer in non-smoking Chinese women: incidence of environmental tobacco smoke exposure and GSTM1/T1 genetic variation. Cancer Causes Control 16: 399-405, 2005.
40. Mannervik B, Awasthi YC, Board PG, et al: Nomenclature for human glutathione transferases. Biochem J 282: 305-308, 1992.
41. Ketterer B, Harris JM, Talaska G, Meyer DJ, Pemble SE, Taylor JB, Lang NP and Kadlubar FF: The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ Health Perspect 98: 87-94, 1992.
42. Guengerich FP, Thier R, Persmark M, Taylor JB, Pemble SE and Ketterer B: Conjugation of carcinogens by theta class glutathione S-transferases: mechanisms and relevance to variations in human risk. Pharmacogenetics 5 (Suppl): 103-107, 1995.
43. Houlston RS: Glutathion S-transferase M1 status and lung cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 8: 675-682, 1999.
44. Benhamou S, Lee WJ, Alexandrie AK, et al: Meta- and pooled analysis of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis 23: 1343-1350, 2002.
45. Raimondi S, Paracchini V, Autrup H, et al: Meta- and pooled analysis of GSTT1 and lung cancer: a HuGE-GSEC review. Am J Epidemiol 164: 1027-1042, 2006.
46. Lee KM, Kang D, Clapper NL, et al: CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among Asian populations. Cancer Epidemiol Biomarkers Prev 17: 1120-1126, 2008.
47. Dialyna I, Miyakis S, Georgatou N and Spandidos DA: Genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes and lung cancer risk. Oncol Rep 10: 1829-1835, 2003.
48. Zhan P, Wang J, Zhang Y, Qiu LX, Zhao SF, Qian Q, WeiSZ, Yu LK and Song Y: CYP2E1 Rsa1/Pst1 polymorphism is associated with lung cancer risk among Asians. Lung Cancer (In press).
49. Eom SY, Zhang YW, Kim SH, Choe KH, Lee KY, Park JD, Hong YC, Kim YD, Kang JW and Kim H: Influence of NQO1, ALDH2, and CYP2E1 genetic polymorphisms, smoking, and alcohol drinking on the risk of lung cancer in Koreans. Cancer Causes Control 20: 137-145, 2009.
50. Hong J, Pan J, Dong Z, Ning SM and Yang CS: Regulation of N-nitrosodimethylamine demethylase in rat liver and kidney. Cancer Res 47: 5948-5953, 1987.
51. Chao C: Associations between beer, wine, and liquor consumption and lung cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 16: 2436-2447, 2007.
52. Chao C, Slezak JM, Caan BJ and Quinn VP: Alcoholic beverage intake and risk of lung cancer: the California Men's Health Study. Cancer Epidemiol Biomarkers Prev 17: 2692-2699, 2008.
53. Shimazu T, Inoue M, Sasazuki S, Iwasaki M, Kurahashi N, Yamaji T and Tsugane S: Alcohol and risk of lung cancer among Japanese men: data from a large-scale population-based cohort study, the JPHC study. Cancer Causes Control 19: 1095-1102, 2008.
54. Howard LA, Ahluwalia JS, Lin SK, Sellers EM and Tyndale RF: CYP2E1*1D regulatory polymorphism: association with alcoholism and nicotine dependence. Pharmacogenetics 13: 321-328, 2003.
55. Wenzlaff AS, Cote ML, Bock CH, Land SJ, Santer SK, Schwartz DR and Schwartz AG: CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. Carcinogenesis 26: 2207-2212, 2005.
56. Chanock SJ and Hunter D: Genomics When the smoke clears... Nature 452: 537-538, 2008.
57. Kiyohara C, Wakai K, Mikami H, Sido K, Ando M and Ohno Y: Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of environmental tobacco smoke and lung cancer: a case-control study in Japanese non-smoking women. Int J Cancer 107: 139-144, 2003.
58. Sobue T, Ajiki W, Tsukuma H, Oshima A, Hanai A and Fujimoto I: Trends of lung cancer incidence by histologic type: a population-based study in Osaka, Japan. Jpn J Cancer Res 90: 6-15, 1999.
59. Toyoda Y, Nakayama T, Ioka A and Tsukuma H: Trends in lung cancer incidence by histological type in Japan. Jpn J Clin Oncol 38: 534-539, 2008.
60. Thun MJ, Lally CA, Flannery JT, Calle EE, Flanders WD and Heath CW Jr: Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 89: 1580-1586, 1997.
61. Devesa SS, Bray F, Vizcaino AP and Parkin DM: International lung cancer trends by histological type: male:female differences diminishing and adenocarcinoma rising. Int J Cancer 117: 294-299, 2005.
62. Sugita M, Izuno T, Tatemichi M and Otawara Y: Meta-analysis for epidemiologic studies on the relationship between smoking and Parkinson's disease. J Epidemiol 11: 87-94, 2001.
63. Fleiss JL and Gross AJ: Meta-analysis in epidemiology, with special reference to study of the association between exposure to environmental tobacco smoke and lung cancer: a critique. J Clin Epidemiol 44: 127-188, 1991.
64. DerSimonian R and Laird N: Meta-analysis in clinical trials. Contr Clin Trials 7: 177-188, 1986.
65. Gonzalez FJ, Jaiswal AK and Nebert DW: Cold Spring Harbor Sym. Quant Biol L1: 879-890, 1986.
66. Kawajiri K, Watanabe J, Gotoh O, Tagashira Y, Sogawa K and Fujii-Kuriyama Y: Structure and drug inducibility of the human cytochrome P-450c gene. Eur J Biochem 159: 219-225, 1986.
67. Comstock KE, Sanderson JS, Claflin G and Henner WD: GST1 gene deletion determined by polymerase chain reaction. Nucleic Acids Res 18: 3670, 1990.
68. Groppi A, Coutelle C, Fleury B, Iron A, Begueret J and Couzigou P: Glutathione S-transferase class mu in French alcoholic cirrhotic patients. Human Genet 87: 628-630, 1991.
69. Zhong S, Howie AF, Ketterer B, Taylor J, Hayes JD, Beckett GJ, Wathen CG, Wolf CR and Spurr NK: Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 12: 1533-1537, 1991.
70. Arand M, Muhlbauer R, Hengstler J, Jaeger E, Fuchs J, Winkler L and Oesch F: A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem 236: 184-186, 1996.
71. Yang CS, Yoo JS, Ishizaki H and Hong JY: Cytochrome P450IIE1: roles in nitrosamine metabolism and mechanism of regulation. Drug Metab Rev 22: 147-159, 1990.
72. Ministry of Health, Labor and Welfare, Japan, 2007.
73. B'chir F, Laouani A, Ksibi S, Arnaud MJ and Saguem S: Cigarette filter and the incidence of lung adenocarcinoma among Tunisian population. Lung Cancer 57: 26-33, 2007.
74. The website of TIOJ〈http://www.tioj.or.jp/index.html〉
75. Houghton AM, Mouded M and Shapiro SD: Common origins of lung cancer and COPD. Nature Med 14: 1023-1024, 2008.
76. Adair-Kirk TL, Atkinson JJ and Senior RM: Smoke particulates stress lung cells. Nature Med 14: 1024-1025, 2008.